Job Trends
Amgen is implementing organizational changes including laying off approximately 300 team members, confirmed Monday.
Labor Market Reports
BioSpace’s Q3 2025 U.S. Life Sciences Job Market Report reveals a turbulent quarter for biopharma hiring, with record declines in job postings, rising layoffs, and cautious employer sentiment shaping the industry’s employment landscape.
BioSpace data show biopharma professionals faced increased competition for fewer employment opportunities during the second quarter of 2025, with increased pressure from further layoffs.
Establishing trust through thought leadership is no longer optional in today’s cautious biopharma market. Learn how strategic insights and targeted outreach can turn awareness into high-converting leads.
Now Hiring
Looking for a biopharma job? Check out the BioSpace list of 12 top companies hiring life sciences professionals like you.
Looking for a biopharma job in New York? Check out the BioSpace list of eight companies hiring life sciences professionals like you.
Of the 25 companies receiving tax incentives in Massachusetts, 23 will add jobs outside of Boston and Cambridge. Medtronic, which is receiving the largest award, will create 220 roles in Billerica. Other recipients include AbbVie, Dyne Therapeutics and Viridian Therapeutics.
Career Advice
It’s likely your worst-case professional scenario – being fired from your job. But being fired doesn’t always have to spell failure for your professional life or your morale level.
THE LATEST
Merck acquired OncoImmune and its COVID-19 therapeutic candidate CD24Fc for $425 million in upfront cash two months after the Phase III asset demonstrated efficacy during an interim analysis.
Late Friday, the FDA gave the green light to Regeneron’s REGN-COV2, a combination of casirivimab and imdevimab.
AstraZeneca and the University of Oxford announced results from an interim analysis of their COVID-19 vaccine, AZD1222. The analysis was from the trials in the UK and Brazil and demonstrated efficacy of up to 90%.
The U.S. Food and Drug Administration (FDA) has a busy end of November planned, with numerous PDUFA dates to address. Here’s a look at the upcoming week.
Although there was quite a bit of clinical trial news overall, the biggest focus was on COVID-19 vaccines, with the three leaders in the U.S. and Europe all presenting clinical trial news. Here’s a look.
In addition to coming sooner than expected, the results are even better than expected. The trial hit all primary efficacy endpoints.
There are similarities between the two COVID-19 vaccine candidates, and a few differences. Here’s a look.
Johnson & Johnson secured more than $1 billion in additional funding for its COVID-19 vaccine research through an expansion of its partnership with the Biomedical Advanced Research and Development Authority.
Late Friday, the regulatory agency rejected the medication of sutimlimab due to deficiencies from a pre-license inspection of a third-party manufacturing facility.
Despite the greenlight from the U.S. Food and Drug Administration as an emergency treatment, there are some questions about how effective the treatment will actually prove to be due to labeling limitations.